In ecosystems where value is both created and at risk, the Codebreaker Mindset helps arrive at the root and defining causes, actions and outcomes. Perhaps it may be months and years before we uncover all the answers to the questions in this article.
Digital health companies have now raised more than $20 billion in 2021, more than any other year. While experts expect to see the dealmaking continue, they raised caution about the challenges of going public with high valuations.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Video from the Health IT and Life Science tracks of our Pitch Perfect contest at INVEST Precision Medicine is now available to view.
Register for INVEST Precision Medicine for free and check out the life science track of the startup pitch contest Pitch Perfect. The presenting companies focus on neurostimulation to treat memory loss, improving clinical outcomes for women's health, wireless drug delivery, opioid risk prediction and more.
More healthcare startups are choosing to go public through mergers with special-purpose acquisition companies— publicly-traded shell companies created with the purpose of taking a private company public. But as the number of SPACs searching for targets increases, will the SPAC bubble burst?
Healthcare technology companies raised a record of $15.3 billion in 2020, according to a report from Silicon Valley Bank. For the first time, digital health companies surpassed biopharma for the number of deals.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Healthcare startups saw smaller amounts of investment after a record-breaking 2018, according to a report from Silicon Valley Bank. Despite the dip in funding, 2019 saw more deals overall, led by increased investment into healthcare technology companies.
Silicon Valley Bank released its healthcare investments and exits trend report for the first half of 2019. It shows, among other things, oncology losing its first-place status in terms of Series A dollars raised.
It was a banner year for biopharma, with records broken in deal values, number of exited unicorns and the biggest-ever biotech IPO. But where do these unicorn valuations come from?
The Silicon Valley Bank parent company's shares were down 2 percent on the news that it would acquire the Boston-based investment bank.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The report also showed 1H18 VC funding already nearly equaled investment in 2017. That's consistent with Silicon Valley Bank's findings on Series A rounds last month.
Investment could be called frothy, but hasn't reached bubble territory yet, SVB report author says.
The company's business model relies on working with independent pharmacies and focuses on patients taking multiple prescription drugs daily.
"I'm a skeptic of public market valuations, but a true believer in biotechnology," said Hans Hinrichs, managing director of Silicon Valley Bank's Life Sciences and Healthcare Group. "We're probably sitting on the biggest opportunity in the history of investment."
Venture capital went up quite a bit in 2015 reaching $59 billion, more than doubling in the last five years - but according to the latest Silicon Valley Bank report, only $2.4 billion went into medical devices.